Strategic collaboration for Takeda

0

A new strategic collaboration has been signed between Takeda and GammaDelta Therapeutics, an Abingworth portfolio company. The operation has a total value of up to $100 million in funding and aims to develop a novel T cell platform based on the unique properties of gamma delta (γδ) T cells derived from human tissues. Possible applications of the immunotherapies derived thereof include the treatment of a broad range of cancers, including solid tumours, and auto-inflammatory diseases. Under the terms of the deal, Takeda will maintain the exclusive right to purchase GammaDelta Therapeutics.

SHARE

LEAVE A REPLY

Please enter your comment!
Please enter your name here